What does the approval of Biogen’s Alzheimers drug Aduhelm, along with the potential approval of others in the pipeline, mean for the future of dementia care?
Watch Dr. Reza Ghomi, practicing neuropsychiatrist and BrainCheck Chief Medical Officer, discuss current barriers to the adoption of new drug treatments, along with the growing need for clinicians to diagnose cognitive impairment earlier.
As addressed by Dr. Maria Carrillo, M.D., Chief Science Officer of the Alzheimer’s Association, one of the largest hurdles to overcome will be ensuring access to the drug and requisite tests for all who benefit. BrainCheck technology can help clinicians identify cognitive impairment earlier to kick off the diagnostic process so that eligible patients can get timely access to treatment.
